Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00323739
Status:
COMPLETED
Last Update Posted:
2013-07-26
First Post:
2006-05-05
Brief Title:
Bevacizumab Avastin and RAD001Everolimusin the Treatment of Advanced Clear Cell Renal Carcinoma
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Phase II Trial of BevacizumabAvastin and RAD001Everolimusin the Treatment of Patients With Advanced Clear Cell Renal Carcinoma
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial will evaluate the combination of bevacizumab RAD001 in patients with metastatic renal cell carcinoma In this trial the investigators will evaluate this combination in patients previously untreated with any anti-angiogenesis agent and patients who have previously received one prior regimen containing an anti-angiogenesis agent
Detailed Description:
All eligible patients will receive
Bevacizumab 10mgkg IV infusion every 2 weeks
RAD001 10 mg by mouth daily
All patients will be evaluated for response after completing two courses 8 weeks of treatment Patients with objective tumor response or stable disease will continue treatment with bevacizumab adn RAD001 on the same schedule Treatment will continue until disease progression occurs
Bevacizumab 10mgkg IV infusion every 2 weeks
RAD001 10 mg by mouth daily
All patients will be evaluated for response after completing two courses 8 weeks of treatment Patients with objective tumor response or stable disease will continue treatment with bevacizumab adn RAD001 on the same schedule Treatment will continue until disease progression occurs
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None